Direxion mRNA ETF
MSGR
MSGR was delisted on the 21st of April, 2023.
0 hedge funds and large institutions have $0 invested in Direxion mRNA ETF in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 0 reducing their positions, and 2 closing their positions.
100% less funds holding
Funds holding: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $198K → $0 (-$198K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$196K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$2.27K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citigroup
New York
| – | -$196K | -14,700 | Closed |
|
|
2
UBS Group
Zurich,
Switzerland
| – | -$2.27K | -170 | Closed |
|
MSGR Hedge Fund Activity: Q2 2023 in Review
0 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Direxion mRNA ETF (MSGR) for Q2 2023, worth a combined $0 — down 100% from $198K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of MSGR and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Citigroup, exiting entirely with an estimated $196K sold.
- 0 institutional investors held Direxion mRNA ETF (MSGR) as of Q2 2023, down from 2 in Q1 2023.
- Funds reported $0 of Direxion mRNA ETF stock for Q2 2023, down 100% quarter-over-quarter.
- 0 funds opened new Direxion mRNA ETF positions in Q2 2023 and 2 closed out, a net change of -2 holders.
- The largest Direxion mRNA ETF seller in Q2 2023 was Citigroup, an estimated $196K sold.
Based on aggregated 13F filings for Q2 2023.